$MRKR Abstract not accepted by ASCO, pancreatic update in 3Q
Agilent Technologies (A) announced that the U.S. Food and Drug Administration has updated its approval of the company's PD-L1 IHC 22C3 pharmDx assay. The assay can now be used as a companion diagnostic to identify a broader range of patients with stage III or metastatic non-small cell lung cancer for first-line treatment with KEYTRUDA, a targeted anti-PD-1 therapy manufactured by Merck & Co. (MRK).
$ZSAN Maxim buy PT $8
Boston Scientific $BSX PT Lowered to $43 at Canaccord Genuity